TGFB1 and ovarian carcinoma: Therefore, in this study, ALDHhigh-expressing ovarian cancer CSCs will be selected by flow cytometry, and then TGF-β signaling pathway inhibitor SB525334 will be used on CSCs to detect the changes in malignant ability of cells together with the changes in TGF-β pathway and EMT key gene expression.